Deepa Jeyakumar, MD, from UC Irvine Health talks about, Midostaurin, the 1st new and approved AML drug in a long time for patients with FLT3 positive AML in the upfront setting at MOASCs Spotlight On® Hematology in Huntington Beach.
Midostaurin is the 1st New and Approved AML Drug in a Long Time – For patients with FLT3 positive AML in the upfront setting
